Zura Bio Limited (ZURA) – What Are Investment Firms Saying About This Stock?

Zura Bio Limited (NASDAQ:ZURA) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $17.00.

A number of equities analysts recently commented on ZURA shares. Wedbush increased their price target on Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. William Blair began coverage on Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. Guggenheim reiterated a “buy” rating on shares of Zura Bio in a report on Friday, October 30th. Wall Street Zen raised shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings upgraded shares of Zura Bio from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, October 28th.

Institutional Trading of Zura Bio

A number of hedge funds have recently modified their holdings of ZURA. Ethic Inc. purchased a new position in shares of Zura Bio in the 3rd quarter valued at about $53,000. Dimensional Fund Advisors LP raised its position in shares of Zura Bio by 83.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 43,135 shares of the company’s stock worth $257,000 after purchasing an additional 19,603 shares during the last quarter. Alps Advisors Inc. raised its stake in Zura Bio by 30.7% in the 3rd quarter. Alps Advisors Inc. now owns 126,053 shares of the company’s stock valued at $524,000 after purchasing an additional 29,639 shares during the last quarter. Bank of America Corp DE lifted its holdings in Zura Bio by 3,007.7% in the 1st quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock valued at $812,000 after purchasing an additional 132,130 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Zura Bio by 3.4% during the 1st quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock worth $1,864,000 after purchasing an additional 10,200 shares during the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Price Performance

ZURA opened at $4.02 on Friday. The firm has a market cap of $385.24 million, a PE ratio of -3.59 and a beta of 0.03. Zura Bio has a 1 year low of $3.25 and a 1 year high of $7.44. The stock has a 50-day moving average price of $4.53 and a 200-day moving average price of $5.22.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.20). As a group, sell-side analysts anticipate that Zura Bio will post -0.82 EPS for the current year.

About Zura Bio

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.